Skip to main content
CSL Ltd. logo

CSL Ltd. — Investor Relations & Filings

Ticker · CSL ISIN · AU000000CSL8 LEI · 529900ECSECK5ZDQTE14 ASX Manufacturing
Open in API
Filings indexed 2,555 across all filing types
Latest filing 2010-10-14 Transaction in Own Shar…
Country AU Australia
Listing ASX CSL

About CSL Ltd.

https://www.csl.com/

CSL is a global biotechnology company that researches, develops, manufactures, and markets a diverse portfolio of medicines. The company operates through distinct business units. CSL Behring provides plasma-derived and recombinant biotherapies for patients with rare and serious diseases, including bleeding disorders, immunodeficiencies, and neurological disorders. CSL Seqirus is a leading provider of vaccines, with a focus on influenza prevention and public health. CSL Vifor specializes in therapies for iron deficiency and nephrology, addressing the full spectrum of kidney disease. Collectively, CSL delivers lifesaving and life-enhancing treatments to a global patient population.

Recent filings

Filing Released Lang Actions
Daily share buy-back notice - Appendix 3E 2 pages ?Kb
Transaction in Own Shares Classification · 100% confidence The document is titled 'Appendix 3E Daily share buy-back notice' and contains detailed information about the company's on-market share buy-back activity, including number of shares bought back, prices paid, and compliance statements. It is a daily notice related to share repurchase activity, not a full financial report or earnings release. The content matches the description of a report on the company's transactions in its own shares. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length is short and focused solely on buy-back details, confirming it is not an announcement of a report but the actual notice of share repurchase activity.
2010-10-14 English
Chairman`s Address to Shareholders 23 pages ?Kb
AGM Information Classification · 95% confidence The document is dated 13 October 2010 and is addressed to the Australian Securities Exchange Company Announcements Office. It contains the Chairman's Address and Managing Director's presentation slides for CSL's Annual General Meeting (AGM) held on that date. The content includes a detailed review of the company's performance, financial results, strategic initiatives, and outlook, typical of presentations made at an AGM. The document explicitly states these materials are to be presented at the AGM. There is no indication that this is the full Annual Report or a financial statement filing, but rather presentation materials for the AGM. The length of the document (15,000 characters) supports it being a substantial presentation rather than a brief announcement. Therefore, the document fits the category of AGM Information (AGM-R).
2010-10-12 English
Results of Meeting 3 pages ?Kb
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal communication addressed to the Australian Securities Exchange regarding the results of an Annual General Meeting (AGM) for CSL Limited. It includes detailed proxy voting results for various resolutions such as election and re-election of directors, adoption of the remuneration report, approval of performance rights grants, and remuneration of directors. The presence of proxy summaries and voting outcomes clearly indicates this is an official announcement of voting results from the AGM. The document length is 3658 characters, which is relatively short and focused on voting results rather than the full AGM materials or presentations. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2010-10-12 English
Final Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities interests of a director who has ceased to be a director, including shares, performance rights, and options. This is a report of personal share transactions and holdings by a company director. The document length is 2726 characters, which is consistent with a detailed director's dealing notice. There is no indication of financial results, management discussion, or other report types. Therefore, this document fits the definition of Director's Dealing (DIRS).
2010-10-12 English
Change to Company Details 7 pages ?Kb
Regulatory Filings
2010-10-11 English
Appendix 3B 7 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, terms, issue price, purpose, and quotation application to the ASX (Australian Securities Exchange). It references specific ASX rules and the Corporations Act, indicating it is a regulatory filing related to capital raising and securities issuance. The document is not a full financial report, earnings release, or management discussion but a formal announcement of new share issuance and application for quotation. This matches the definition of a 'Share Issue/Capital Change' announcement (SHA). The document length is over 10,000 characters and contains substantive details about the share issue, not just a brief notice or report publication announcement.
2010-10-07 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.